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AutoantibodyDermatomyositis, polymyositis and immune-mediated necrotising myopathy are major forms of idiopathic
inﬂammatorymyopathy.We reviewhere recent developments inunderstanding the pathology andpathogenesis
of these diseases, and characterisation of autoantibody biomarkers. Dermatomyositis is traditionally considered
to be due to a complement-mediated microangiopathy but the factors responsible for complement activation
remain uncertain. Recent studies have emphasised the importance of the type I interferon pathway in the
pathogenesis of the disease and have identiﬁed autoantibodies with speciﬁcities for different clinical subgroups
of patients. Polymyositis is characterised by a cytotoxic T cell response targeting as yet unidentiﬁed muscle
antigens presented by MHC Class I molecules, and can occur in isolation but is more often part of a multi-
systemic overlap syndrome. The immune-mediated necrotising myopathies are heterogeneous and are
distinguished from polymyositis by the sparseness of inﬂammatory inﬁltrates and recognition of an association
with speciﬁc autoantibodies such as anti-SRP and anti-HMGCR in many cases. This article is part of a Special
Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
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. Mastaglia).1. Introduction
The idiopathic inﬂammatory myopathies (IIM) are currently classi-
ﬁed into four major categories: dermatomyositis (DM), polymyositis
(PM), inclusion body myositis (IBM) and the immune-mediated
necrotising myopathies (IMNM). Although the clinical presentations
of DM and PM are similar, manifesting usually as subacute painless
proximal limb weakness, plus the distinctive skin manifestations of
DM, immunopathologic observations and more recent gene expression
and proteomic analyses have provided convincing evidence that the
underlying pathogenetic mechanisms in these disorders are fundamen-
tally different. An alternative method of classiﬁcation based upon the
major histopathological features in each condition has recently been
proposed [1].
Polymyositis is generally regarded as a prototypic T cell-mediated
autoimmune myopathy, whereas DM has traditionally been attributed
to a humoral-driven microangiopathy, although the putative autoanti-
bodies and their targets have yet to be identiﬁed, and there is increasing
evidence implicating the type I interferon pathway in the pathogenesis
of the disease. In contrast, IBM is characterised clinically by a more
selective pattern of muscle weakness, protracted clinical course and
poor response to treatment, and pathologically by a combination of a
T cell dominant inﬂammatory response and myoﬁbre degeneration.
The IMNMs are a heterogeneous group of necrotising myopathies,
which in some cases are associated with speciﬁc autoantibodies such
Table 1
Clinical, serological and pathological features of immune-mediated inﬂammatory myopathies.
Dermatomyositis Polymyositis IMNM
Muscle weakness Proximal predominant (UL N LL) Proximal predominant Proximal + distal
Skin involvement + − −
Association with CTD + ++ +
Association with malignancy + + −
Association with viral infections
(HIV, HTLV-1, hepatitis C)
+ + +
Autoantibodies (target antigens) Mi-2, MDA5, TIF-1, NXP-2 U1-snRNP, PM-Scl, Antisynthetase SRP, HMGCR
Histopathology
Myoﬁbre necrosis Fibre groups, perifascicular, microinfarcts Single ﬁbres Single ﬁbres
Perifascicular atrophy + − −
Inﬂammatory inﬁltrates CD4+ T cells, B cells, pDCs (BDCA2+) CD8+ T cells, plasma cells (CD138+),
mDCs (BDCA1+)
Macrophages (CD68+/CD163+)
MAC (C5b-9) ++ − +/−
MHC-I/II ++ ++ +/−
Capillary depletion ++ +/− −
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pletely understood. The major clinical and pathological features of
DM, PM and IMNM are summarised in Table 1.
This review provides an update on recent advances in our under-
standing of the cellular and molecular pathogenesis of DM, PM and
IMNM, and progress in the characterisation of autoantibody biomarkers
for the different subgroups of immune-mediated inﬂammatory myopa-
thies. The pathogenesis of IBM, which is a distinctive disease given its
additional myodegenerative features, has been reviewed elsewhere
[2–4], and is dealt with in a separate review by Askanas and Engel in
this issue.2. Dermatomyositis
2.1. Clinical aspects
As shown in Table 2, DM can be classiﬁed into childhood and adult
forms, and subgroups in which the cutaneous manifestations predomi-
nate and muscle weakness is minimal or absent (amyopathic DM), or
there are systemic features, or the condition is associated with an un-
derlying malignancy, or is part of an overlap syndrome. Although indi-
vidual cases of DM can be classiﬁed into a particular category based on
the presence and severity of skin and muscle involvement, it is likely
that they are all part of a disease spectrum in which the skin and
muscles are affected to a variable degree. When the typical DM rash is
present on the face (heliotrope rash), hands and elbows (Gottron's
papules), and trunk (shawl and V signs) it is diagnostic of the condition.
There is usually a predominantly proximal pattern of muscle weakness,
which may be more severe in the upper limbs, and in some cases is as-
sociated with myalgia and edema of the overlying skin. Subcutaneous
calcinosis commonly occurs, particularly in childhood cases, but also
in some adult cases [5,6]. In some cases the skin changes may be tran-
sient or are relatively inconspicuous when the patient is ﬁrst seen, and
may only become obvious at a later stage. In such cases amistaken diag-
nosis of PM or of a non-inﬂammatory myopathy may be made prior to
muscle biopsy.Table 2
Classiﬁcation of dermatomyositis (DM) and associated autoantibodies.
Autoantibodies
Juvenile DM Anti-NXP-2
Adult DM Anti-Mi-2
DMwith systemic manifestations Anti-MDA5
DMwith systemic manifestations Anti-SAE
Cancer-associated DM Anti-TIF-1γ, TIF-1α
Amyopathic DM Anti-MDA52.2. Immunopathology
DM is traditionally considered to be an ischemic myopathy resulting
from a complement (C5b-9)mediated injury to endothelial cells leading
to depletion of themuscle capillary bed and tomuscle ﬁbre necrosis and
the characteristic perifascicular pattern of muscle ﬁbre atrophy [7].
However, it remains unclear how the complement pathway is activated
in DM and autoantibodies targeting endothelial cell antigens have never
been identiﬁed. The inﬂammatory cells in the perimysial and perivas-
cular inﬁltrates comprise mainly B cells and CD4+ T helper cells [8]
including interferon-α (IFNα) producing plasmacytoid dendritic cells,
IFNγ producing Th1 cells and interleukin 17 (IL-17) producing Th17
cells (Fig. 1) [9,10]. The activation of CD4+ T cells may involve the
expression of Toll like receptors (TLR) 4 and 9 [11]. IL-17 is thought to
facilitate the migration of mononuclear cells to the muscle as well as
inducing up-regulation of muscle membrane MHC-I molecules [12]. B
cell-activating factor (BAFF), which is involved in the maintenance of
mature B cells and plasma cells, is also up-regulated [13]. It is postulated
that deposition of immunoglobulins on intramuscular capillaries
activates the complement cascade, triggering the production of pro-
inﬂammatory cytokines and chemokines, which in turn up-regulate
the expression of adhesion molecules on endothelial cells leading toFig. 1. Schematic representation of the involvement of CD4+and CD8+T cells, B cells and
the Th1, Th17 and type I interferon pathways in inﬂammatory myopathies. Plasmacytoid
dendritic cells (pDCs) produce type I interferons (INFα/β), which results in up-regulated
expression of INF-stimulated genes in muscle (MxA, ISGF-15, IRF-7…) and blood (I-TAC,
IRF-7, IP-10, MCP-1…) in DM. The differentiation of CD4+ T cells is polarised to Th1
and Th17 responses, the former activating macrophages and the latter producing the
pleiotropic cytokine IL17. CD4+ T cells are also necessary for the differentiation of B
cells and antibody production. A Th1 response is thought to be primarily involved in
IMNM [15], while in PM and IBM CD8+ T cells are the primary effector cells.
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of plasmacytoid dendritic cells [5,14].2.3. Type I interferon pathway
Since the ﬁnding that interferon inducible genes are highly up-
regulated in DM tissues [16], the importance of the type I IFN pathway
has been under the spotlight. Subsequent studies demonstrated strong
expression of the type I IFN-inducible proteins ‘humanmyxovirus resis-
tance 1 protein’ (MxA) and ‘IFN-stimulated gene 15’ (ISG15) in DM
muscle, particularly in capillaries and perifascicular muscle ﬁbres [17].
It has also been shown that blood, muscle and skin all share the same
‘type I IFN signature’ of gene expression in DM [18]. Moreover, serum
levels of IFNα, IFNβ and several type I IFN-regulated proteins (IFN-
inducible α T cell chemoattractant, IFN-γ-inducible 10-kD protein,
monocyte chemotactic proteins 1 and 2), as well as the pro-
inﬂammatory cytokine IL-6, are increased in DM and are potential bio-
markers of disease activity [19–21]. Interestingly, IFNβ, but not IFNα,
was found to be associated with up-regulation of IFN-related genes in
serum [22] and in muscle tissue, more so in juvenile than adult DM
[23]. Moreover, DM sera with nucleic acid-associated antibodies were
found to activate the IFNα expression, suggesting that up-regulation of
type I IFN may be secondary to the production of autoantibodies [24].
While the up-regulation of type I IFN inDM is undisputable, its signif-
icance and speciﬁcity in the pathogenesis of the disease remains to be
decided. For example, in a study comparing type I IFN and other cytokine
signatures (e.g. granulocyte–monocyte colony-stimulating factor, IL-10,
IL-13, IL-1β and TNFα), although the type I IFN signature in the blood
was the most markedly up-regulated in inﬂammatory myopathies,
type I IFN expression levels were comparable in DM and PM [25]. Simi-
larly, the pattern of type I IFN signature in the skin in DMwas similar to
that seen in systemic lupus erythematosus and herpes simplex virus-2
infection [26]. Moreover, whether and how the accumulation of IFN-
inducible proteins contributes to the perifascicular atrophy and muscle
ﬁbre injury remain to be determined. Type I IFNs may lead to over-
expression of MHC-I molecules (Fig. 2) which may have pathogenicFig. 2.Dermatomyositis: A. endomysial and perivascularmononuclear inﬂammatory inﬁltrate; B
cells and macrophages; C & D perifascicular ﬁbre regeneration and atrophy. A–C: haematoxylieffects in their own right through induction of endoplasmic reticulum
stress and the unfolded protein response in muscle ﬁbres [27,28].
2.4. Microvascular pathology
The early studies of DeVisser et al. (1989) andEmslie-Smith andEngel
(1990) showed that membrane attack complex (MAC) deposition and
degenerative changes in intramuscular capillaries, and depletion of capil-
lary numbers, occur even before other structural changes in the muscle
[29,30]. Subsequent studies have conﬁrmed the capillary depletion
which is associatedwith increased activation of endothelial cells and in-
creased expression of vascular endothelial growth factor (VEGF) in
muscle ﬁbres [31,32]. It has been shown that perimysial intermediate-
sized vessels are also affected and are closely associated with regions
of perifascicular ﬁbre atrophy [33]. A recent study using 3D-
reconstruction ofmicrovessels in serial sections of DMmuscles, including
amyopathic cases, has demonstrated that rather than random loss of cap-
illaries, it is the whole microvascular unit, that includes 6–8 endomysial
capillaries branching from a terminal arteriole, that is lost [34]. On the
basis of these ﬁndings the authors concluded that muscle ischaemia
probably results from inﬂammatory narrowing of perimysial arcade
arteries and that activation of the complement cascade in endomysial
capillaries may be secondary to ischaemic–reperfusion injury.
The 250 Å tubuloreticular inclusions in vascular endothelial cells,
ﬁrst described by Banker [35], are found both in juvenile and adult
DM, and are generally regarded as a reliable marker for distinguishing
DM from other inﬂammatory myopathies [36], although they have
also been reported in myositis with overlap syndrome [37]. The origin
of these structures is uncertain, but may be related to the effects of
IFNα which is expressed in capillaries in DM and PM [9,38] and has
been shown to induce the formation of tubuloreticular inclusions in
lymphocytes in vitro [39].
2.5. Autoantibodies
A number of autoantibodies have a high speciﬁcity for DM, but their
role in the pathogenesis of the muscle damage remains unclear. One of. fragmentation of perimysial connective tissue and inﬁltrationwith granularmononuclear
n and eosin stain; D: MHC-I immunohistochemistry.
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component of the nucleosome remodelling deacetylase complex
(NuRD) [40,41]. Anti-Mi-2 occurs mainly in adult cases, and is rare in
juvenile DM [42]. Patients with anti-Mi-2 tend to have typical DM skin
changes, higher serum CK levels and a good response to treatment,
and are less likely to develop interstitial lung disease or cancer [43].
The reported frequency of anti-Mi-2 antibodies varied greatly (3–60%)
in DM cohorts from different geographic regions [43,44] and was
found to correlate with the level of ultraviolet light exposure in a large
multicentre international study and in a study from the United States
[44–46]. However, this was not conﬁrmed in a more recent study
from Central America [43]. A link with ultraviolet light exposure was
supported by the ﬁnding of elevated levels of Mi-2 in cultured
keratinocytes after exposure to ultraviolet B light [46]. Increased
expression of Mi-2 was demonstrated in regenerating muscle ﬁbres in
DM biopsies, and it has been proposed that high levels of expression
of the antigen in regenerating cells in muscle and epidermis may play
a part in sustaining the autoimmune process [41]. Other myositis-
speciﬁc antibodies are rare in DM, with the exception of anti-Jo-1
which was present in up to 16% of adult cases in a large multicentre
European study [47].
A number of newer autoantibodies which appear to be associated
with particular subgroups of DM cases have been characterised in re-
cent years (Table 2). Antibodies to the 155/140 kDa nuclear proteins
were ﬁrst shown to be associated with DM and a higher risk for cancer
[48], and this has been conﬁrmed in a recent review and meta-analysis
of published series [49]. The two proteins have been identiﬁed as tran-
scription intermediary factor 1γ and 1α respectively (TIF-1γ, TIF-1α),
with an additional less frequent antigen TIF-1β from the same family
[50]. Anti-TIF-1 antibodies occur in both juvenile and adult DMpatients,
with a positivity rate of 16–23% [43,50,51] and adult patients have a
higher incidence of malignancy, whereas juvenile and young adult
patients do not [43,50]. It has been proposed that the TIF proteins are
implicated in carcinogenesis and that anti-TIF-1 antibodies generated
as part of an anti-tumour response may cross-react with other tissues
such as muscle and skin expressing high levels of the antigens, and
thereby propagate the autoimmune process [41].
An association with antibodies to CADM-140 (now termed MDA5)
was ﬁrst described in Japanese patient cohorts with clinically amyo-
pathic DM and interstitial lung disease [52], and subsequently also in
other racial groups [53–55]. The antibody recognises ‘interferon
induced with helicase C domain protein 1’ (IFIH1), now known as ‘mel-
anomadifferentiation-associated gene 5’ (MDA5) [56,57], which is a cy-
toplasmic RNA-speciﬁc helicase belonging to the RIG-I-like receptor
family. MDA5 participates in the innate immune response to viruses
and is also a potential activator of type I IFN transcription. Subsequent
studies of patients with anti-MDA5 antibodies have shown that
they have more severe skin manifestations, a higher incidence of
rapidly progressive interstitial lung disease, less muscle involvement
and lower serum creatine kinase (CK) levels [54,58]. However, there
appears to be considerable racial and ethnic variation in the frequency
of anti-MDA5 and in the associated clinical phenotype. In a recent
report from the USA, only 6.9% of DM patients had anti-MDA5 anti-
bodies, andmost of these had overt myopathywith interstitial lung dis-
ease and a clinical phenotype resembling the antisynthetase syndrome
[59].
Antibodies to the nuclear matrix protein 2 (NXP-2) (originally
termed anti-MJ) are present in up to 25% of cases of juvenile DM and
are associated with more severe muscle weakness, calcinosis, joint
contractures and intestinal vasculitis [60–63]. Anti-NXP-2 antibodies
were also found in 30% of adult DM cases in an Italian cohort [64],
being more common in patients of younger age, but were present in
only 1.6% of cases in a large Japanese series [65]. These ﬁndings again
highlight the considerable racial and geographic differences in the
frequencies of DM associated antibodies which are also known to be
inﬂuenced by genetic factors, particularly the HLA genotype [66,67].Anti-small-ubiquitin-like-modiﬁer-activating-enzyme (anti-SAE)
antibodies are reported to have a prevalence of 8% in Caucasian and
1.8% in Asian DM patients [68,69]. The clinical spectrum of patients
with anti-SAE antibodies does not seem to be different from those
without anti-SAE antibodies. However, the former have a higher repre-
sentation of HLA-DRB1*04-DQA1*03-DQB1*03 genotype [69].
In contrast to the aforementioned autoantibodies, the prevalence of
anti-dense ﬁne speckled 70 antibodies (anti-DFS70) has been reported
to be lower in DM than in normal individuals [70]. It is of interest that
in this Japanese cohort, of the four patients with both anti-MDA5
and anti-DFS70 antibodies, three patients showed decreased anti-
MDA5 and increased anti-DFS70 antibody levels during remission,
while in the fourth patient who died anti-MDA titres were unchanged
and anti-DFS70 antibody levels were essentially negative. It is tempting
to speculate that anti-DFS70 antibodies, which target the lens
epithelium-derived growth factor (LEDGF), may be protective against
the development of DM [6].
2.6. Genetic susceptibility
Similar to IBM, DM also shows a predisposition for speciﬁc human
leukocyte antigen (HLA) genotypes, but to different alleles. HLA-
DQA1*0501 is associated with increased susceptibility to juvenile DM
[42]. The tumour necrosis factor alpha (TNFα) gene lies between the
HLA-B and HLA-DR3 loci. An A/G polymorphism in the promoter region
of TNFα that leads to augmented TNFα production is highly represented
in both juvenile and adult DM [44,71]. A pilot study on 33 DM patients
identiﬁed several single nucleotide polymorphisms in IL-10 in associa-
tion with DM [72]. A recent large genome-wide association study has
conﬁrmed the strong association with the major histocompatibility
complex (MHC) region in both juvenile and adult cases of DM, and also
demonstrated an association with polymorphisms in three other non-
MHC genes previously associated with other autoimmune diseases,
phospholipase C like-1 (PLCL1), B lymphoid tyrosine kinase (BLTK), and
chemokine (C-Cmotif) ligand 21 (CCL21) [46]. Taken together, themajor-
ity of genes linked to an increased susceptibility for DM are involved in
the inﬂammatory process, illustrating the pivotal role of inﬂammation
in DM aetiology. Additionally, a polymorphism in the protein tyrosine
phosphatase N22 gene (PTPN) is associated with juvenile DM but not
adult DM [73].
A recent genome-wide DNA methylation proﬁling study of juvenile
DM muscle biopsies has provided novel epigenetic data demonstrating
alteredmethylation in a number of genes encoding transcription factors
and cell cycle regulators [74]. These ﬁndings indicate the capacity for
self-renewal in damaged muscles in juvenile DM, and that certain criti-
cal genes are epigenetically altered as a result of the disease process.
Another study on IBM and PM presented evidence for increased cell
cycle entry in these two diseases, possibly leading to activated cell apo-
ptosis [75]. Whether DM has a similar proﬁle of dysregulated cell cycle
regulatory proteins awaits clariﬁcation.
2.7. Maternal microchimerism in childhood DM
It has been suggested that the presence ofmaternally derived cells in
the circulationmay contribute to the pathogenesis ofmultisystem auto-
immune disease and may be comparable to the graft-vs-host disease
which occurs after bone marrow transplantation in HLA-incompatible
donors. In a cohort of 72 cases of juvenile DM maternal chimeric cells
were identiﬁed in 83% of children with juvenile DM compared with
23% of unaffected siblings and 17% of healthy controls, and was associ-
ated with carriage by the mother of the HLA-DQA1*0501 allele which
is a signiﬁcant risk factor for juvenile DM [76]. In another study, evi-
dence of maternal microchimerism was found in skin and muscle sam-
ples from 10/10 cases of juvenile DM comparedwith 2/10 cases of other
muscle disorders [77]. These ﬁndings suggest that maternal chimerism
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ther investigation.
2.8. MicroRNAs
MicroRNAs (miRNAs) are a group of small noncoding RNAs that si-
lence gene expression by base pairing with the 3′ untranslated region
of genes. Altered expression of miRNA has been found in DM, with
miR-146b and miR-155 being the most up-regulated and miR-1, miR-
133, miR-206, miR-11040 and miR-30a-3p down-regulated [78,79].
However, the disturbance of miRNA expression is not unique to DM,
as the majority of miRNAs with changed expression in DM also show
similar trends in PM, IBM and muscular dystrophies. It is found that in-
creased pro-inﬂammatory cytokines reduce the expression of miR-1,
miR-133 and miR-206 that are involved in myoblast differentiation
andmuscle regeneration as well as CD4+helper T cell maturation, pro-
viding a novel link between inﬂammation and muscle damage via
miRNA-mediatedpost-transcriptional regulationofgeneexpression [79,
80]. miR-126 inhibits the translation of vascular cell adhesion molecule
1 (VCAM1) and is repressed in serum and muscle of juvenile DM
patients with a disease duration of under 2 months, suggesting the
involvement of miR-126 in the recruitment of lymphocytes in the
early stage of DM [81]. The level of miR-223, which inhibits the expres-
sion of protein kinase C ε type (PKCε) that regulates multiple cellular
processes, is reduced in skin tissues from DM patients, potentially lead-
ing to cell proliferation in Gottron's papules [82]. miR-7 is also reduced
in the serum and skin but its signiﬁcance in the pathogenesis of DM
requires further investigation [83].
3. Polymyositis
3.1. Clinical considerations
The existence of PM as an isolated entity has been through vigorous
debate, especially since the separation of IBM from PM [84–88].
The controversy relates to whether PM can occur as a primary muscle-
speciﬁc disease or merely as part of a more widespread connective
tissue disease or autoimmune disorder, considering their frequentA
C
Fig. 3. Polymyositis: endomysialmononuclear inﬂammatory inﬁltrate (A–D);myoﬁbre invasion
expression (B). A & C: haematoxylin and eosin; B: MHC-I immunohistochemistry; D: modiﬁedcoexistence. Although isolated PM is probably not as rare as has been
suggested [88], several studies have found that it is the least common
form when compared with DM and IBM [89–91] except in Japan
where PM outnumbers the other varieties of IIM [91,92].
PM typically manifests as a painless proximal myopathy with sub-
acute onset and is usually responsive to corticosteroids and immune
suppression. It occurs mainly in adults, but can occasionally present in
childhood, although much more rarely than juvenile DM [93]. In addi-
tion to this classic phenotype there have also been reports of a distal
variant which presents with weakness mainly in the upper limbs and
a good response to treatment [94]. Other restricted variants include
cases with dropped head or camptocormia due to involvement of the
paraspinal muscles [95–98].3.2. Immunopathology
Since the discovery of CD8+T cell predominant lymphocytes invad-
ing non-necrotic ﬁbres in PM and IBM [99], the interaction of antigen-
presenting MHC-I molecules (Fig. 3) and effector CD8+ T cell, and the
subsequently activated cytotoxicity in terms of the release of perforin,
has been considered the core pathogenic event in PM (Fig. 1) [100].
CD8+ T cells, but not CD4+ T cells, clonally propagate in response to
auto-antigens processed in muscle ﬁbres and presented by surface
MHC-I molecules [101–103]. It is worth mentioning that although the
restricted clonal expansion indicates a limited number of antigens, the
usage of adopted complementarity-determining region seems to be
different in different patients, raising doubt as to whether there is a
common self-antigen in PM.
The interaction of Fas on muscle ﬁbres and Fas ligand on invading
CD4+ T cells leads to cell apoptosis while expression of Bcl-2 is protec-
tive [104,105]. The invadingmononuclear cells have also been shown to
include antigen-presenting BDCA-1+myeloid dendritic cells as well as
antibody-secreting CD138+ plasma cells [106,107]. Another study
identiﬁed that fascin-positive mature dendritic cells greatly predomi-
nate over langerin-positive immature dentritic cells in PM as well as
DM, suggesting that the maturation of dendritic cells may take place
outside the muscle rather than locally [108].B
D
bymononuclear cells (C, arrowhead);myoﬁbre necrosis (C, D); and diffuseMHC-I antigen
Gomori trichrome.
Table 3
Potential triggers for immune-mediated necrotising myopathies.
Anti-signal recognition particle antibodies
Statin therapy (anti-HMGCR antibodies)
Antisynthetase antibodies
Malignancy
Connective tissue diseases
Viral infections (HIV, hepatitis C)
627Y.-B. Luo, F.L. Mastaglia / Biochimica et Biophysica Acta 1852 (2015) 622–632Although in both PM and IBM the inﬁltrating T cells are thought to
proliferate and differentiate locally inmuscle [109], ﬁndings in amyosi-
tis mouse model have shown that CD8+ T cells also proliferate in local
draining lymph nodes [110]. The autoinvasive T cells and macrophages
express monocyte chemoattractant protein-1 (MCP-1), which facili-
tates the recruitment of monocytes [111]. De Paepe showed the pres-
ence of pro-inﬂammatory chemokines as well as heat shock proteins
and inducible nitric oxide synthase in proximity to the invaded muscle
ﬁbres, suggesting their involvement in the cytotoxicity of T cells [112].
The lysosomal cysteine protease cathepsin B, which is involved in
antigen presentation by MHC-II [113], is also up-regulated in PM
[114]. The pro-inﬂammatory cytokine, macrophage inhibition factor
(MIF) is up-regulated and detected in necrotic and invaded non-
necrotic PM muscle ﬁbres, suggesting its participation in recruitment
of macrophages as the initial step of muscle regeneration [115].
3.3. Fibroblasts
In both PM and IBM, CD90+ CD34− ﬁbroblasts have also been
shown to invade non-necrotic muscle ﬁbres [116]. However, in PM
the basement membrane is disrupted and the ﬁbroblasts are in direct
contact with the plasma membrane, whereas in IBM they are
ensheathed by the basement membrane. The pathological impact of
these invading ﬁbroblasts in PM may be pro-inﬂammatory and they
may contribute to the breakdown of the sarcolemma.
3.4. Microvascular changes
It is of interest that muscle capillary numbers have been found to be
reduced in the early stages of PM as well as DM, and VEGF, which
promotes angiogenesis, is up-regulated [32]. The signiﬁcance of these
ﬁndings is unclear but they suggest that hypoxia may also play a part
in the pathophysiology of PM.
3.5. Autoantibodies and overlap syndromes
As shown in Table 1, PM can be associatedwith a number of different
autoantibodies and other autoimmune disorders, and is then classiﬁed
as belonging to one of the ‘overlap syndromes’. The best characterised
of these are: mixed connective tissue disease (MCTD), scleroderma–
myositis overlap syndrome, and the antisynthetase syndrome, although
as has been pointed out previously, there is a certain amount of overlap
in their clinical manifestations [88].
MCTDmyositis is associatedwith other systemic features of system-
ic sclerosis or SLE such as Raynaud's phenomenon, sclerodactyly and
synovitis, and there are high titres of antibodies to a 70-kD ribonuclear
protein complex (anti-U1 snRNP). The scleroderma–myositis overlap
occurs in only a small minority of cases of scleroderma and is
characterised by the presence of antibodies to the nucleolar PM-Scl
antigen complex (anti-PM-Scl), which is rare in scleroderma and
other forms of myositis but, when present, is a strong marker for the
scleroderma–myositis overlap syndrome [84].
In the antisynthetase syndrome, which is associatedwith antibodies
to one of the tRNA synthetases, myositis is accompanied by other
systemic features including interstitial lung disease, Raynaud's phe-
nomenon, deforming arthropathy and skin changes in the hands, and
the condition is relatively resistant to treatment [117]. The most preva-
lent antisynthetase antibody is anti-Jo-1 (anti-histidyl tRNA synthe-
tase), which is present in about 20% of cases of PM and DM [118–120]
Pathologically, perimysial connective tissue damage with associated
CD68+ histiocytes, perivascular CD4+ T cells and perifascicular
ﬁbre necrosis and regeneration are described in cases with anti-Jo-1
[1,121]. Other rarer antisynthetases associated with this syndrome
include anti-PL-12 (alanyl-tRNA synthetase), anti-PL-7 (threonyl-tRNA
synthetase), anti-EJ (glycyl-tRNA synthetase), anti-OJ (isoleucyl-
tRNA synthetase), anti-KS (asparaginyl-tRNA synthetase), anti-Zo(phenylalanyl-tRNA synthetase) and anti-Ha (tyrosyl-tRNA synthetase)
[122].
4. Immune-mediated necrotising myopathies (IMNM)
The IMNMs are a heterogeneous group of acquired myopathies
which are distinguishable from DM and PM on clinical and pathological
grounds, and are amenable to treatment with immune therapies [123].
As shown in Table 3, they can be classiﬁed into a number of different
categories, including cases associated with malignancy, connective
tissue disease or viral infections, and those associated with speciﬁc au-
toantibodies such as anti-SRP, anti-HMGCR and antisynthetase antibod-
ies which are putatively involved in the pathogenesis of the necrotising
myopathy. Although inﬂammation is usually lacking (Fig. 4), IMNM is
considered to be autoimmune in nature because of immunostaining
for C5b-9 and MHC-I in some cases, association with autoantibodies
and other immune disorders, and response to immune therapy [124].
4.1. Myopathy associated with anti-SRP antibody
The anti-signal recognition particle (SRP) antibody was previously
considered as one of the group of myositis-speciﬁc antibodies that are
associated with PM or DM [125,126]. This notion has since changed
and myopathy with anti-SRP antibody now stands as a separate entity
which is distinguishable from PM and DM, and which is less frequently
associated with other concomitant autoimmune or connective tissue
diseases. It is characterised clinically by rapidly progressive and at
times more chronic proximal muscle weakness, with high serum CK
levels, and relative resistance to treatment with conventional immune
therapies, and pathologically by an active necrotising myopathy, with
a relatively inconspicuous or absent inﬂammatory inﬁltrate, and a pre-
dominance of macrophages [15]. In contrast to PM and DM, muscle in-
ﬂammation is never a dominant feature in SRP-associated myopathy
and up-regulation of MHC-I antigen is not a consistent ﬁnding. The ob-
servation of a correlation between serum levels of the antibody and CK
levels, and that following plasmapheresis antibody titres fall as clinical
improvement occurs, favours a causal role for the antibody [127]. The
ﬁnding in some cases of C5b-9 deposition on endomysial capillaries
and non-necrotic muscle ﬁbres [126] suggests that a complement-
dependent antibody-mediated mechanism of muscle ﬁbre injury may
be involved.
SRP is a cytoplasmic ribonucleoprotein complex that transfers newly
synthesised peptides that are destined for secretion or membrane
localisation from ribosomes to the ER for further processing [128]. It is
composed of a 7SL RNA sequence and six protein units with molecular
weights of 9, 14, 19, 54, 68 and 72 kDa respectively. The anti-SRP anti-
body associated with necrotising myopathy mainly targets the 54 kDa
protein that binds to the nascent polypeptides emerging from the
ribosome as well as the SRP receptors on the endoplasmic reticulum
membrane [129].
It is not clear how the anti-SRP antibody leads tomuscle ﬁbre necro-
sis, or why muscle is predominantly affected when the SRP is ubiqui-
tously expressed. The anti-SRP antibody has been shown to interfere
with the association of SRP and the signal sequence of the peptide,
as well as the SRP receptor-mediated peptide translocation to the
endoplasmic reticulum [129] and would be expected to disrupt the
A B
C D
Fig. 4. Immune-mediated necrotising myopathy (A & B associated with prolonged statin therapy; C & D idiopathic case): (A) muscle ﬁbre necrosis with sparse inﬂammatory inﬁltrate;
(B) diffuse sarcolemmal and sarcoplasmic MHC-I expression; (C) necrotising myopathy with (D) scattered macrophagic inﬁltrate. A & C: haemotoxylin and eosin; B and D: MHC-I and
CD163 immunohistochemistry respectively.
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teins. Proteomic studies on patients with SRP-associated myopathy
would be able to clarify this issue. A recent study has demonstrated
anti-SRP antibody binding and associated complement products on
the surface ofmuscleﬁbres in biopsies fromcases of anti-SRP-associated
IMNM [130]. In the same study it was also shown that incubation of
human myoblast cultures with anti-SRP positive sera leads to aberrant
expression of the SRP protein on the surface of myoblasts and induced
cell lysis through a complement-dependent process. These ﬁndings
point strongly to an antibody-mediated complement-dependent mech-
anism of muscle ﬁbre injury in anti-SRP-associated IMNM.
4.2. Anti-HMGCR associated myopathy
Statins, or 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR)
inhibitors, have long been known to cause a spectrum of muscle
symptoms ranging from simple myalgia to a more severe necrotising
myopathy, and at times even fatal rhabdomyolysis [131]. The risk of
myopathy varies with the different statins and predisposing factors in-
clude age, female gender, and other co-morbidities and concomitant
medications. In addition, the importance of genetic predisposition is
being increasingly recognised and has been reviewed recently [132].
The genes so far identiﬁed that can inﬂuence susceptibility to statin
myopathy include: SLCO1B1 (which encodes an anion transmembrane
hepatic statin transporter protein) [133]; CYP2D6 and CYP3A5 (hepatic
cytochrome P450 2D6 and 3A5 enzymes that metabolise statins) [134,
135]; EYS (eyes shut homologue that is involved in the Notch pathway)
[136]; ABCB1 (the efﬂux transporter p-glycoprotein) [137,138]; and
GTAM (glycine amidinotransferase that participates in the synthesis of
creatine) [139]. Several pathomechanisms have been proposed for
statin myotoxicity, including reduced cholesterol levels [140], impaired
post-translational processing (prenylation and glycosylation) of pro-
teins [141], coenzyme Q10 deﬁciency [142], mtDNA depletion [143],
disturbance of the ubiquitin-proteasome and lysosomal pathways
[144,145], and activation of apoptosis [146].While themajority of cases of statin myopathy are self-limiting, and
there is progressive improvement of muscle symptoms and normalisa-
tion of CK levels once the statin is discontinued, it is now recognised that
a small subgroup of patientswhodevelop an IMNMsymptoms continue
to progress, or may even ﬁrst develop after the statin is withdrawn
[147]. In these patients, an autoimmune process is initiated, as demon-
strated by the presence of a highly speciﬁc anti-HMGCR antibodywhich
targets the cytoplasmic domain of HMGCR [148] andwhich is not found
in patients with other forms of statin myopathy [149,150]. The levels of
the antibody correlate with serum CK levels as well as upper limb
strength,making it a suitablemarker for disease activity [151]. It is note-
worthy that the antibody may also be found in some patients without
prior statin exposure [148]. It was also found that the expression of
HMGCR is up-regulated in regenerating muscle ﬁbres in biopsies from
anti-HMGCR-positive patients (Fig. 5) and it was postulated that the
persistent over-expression of the autoantigen may be responsible for
sustaining the autoimmune process even after the statin is withdrawn.
MHC-I antigen has been shown to be up-regulated on the surface of
non-necrotic ﬁbres of statin-associated IMNM [152], but statin alone
does not induce over-expression of MHC-I in vitro, suggesting synergis-
tic effects of other unknown factors [153]. The HLA-DR1*11:01 allele is
associated with the development of anti-HMGCR antibody-positive
IMNM, suggesting a role of the molecule encoded by this allele in the
antigen-presentation process [154].
4.3. IMNM associated with antisynthetase antibodies
Patients with antibodies to histidyl tRNA synthetase (Jo-1) or the
other tRNA synthetasesmay also develop IMNM,with symptomsofmy-
algia ormuscle weakness and high serumCK,with orwithout other fea-
tures of the antisynthetase syndrome such as interstitial lung disease,
arthropathy and skin changes [123]. Pathological descriptions include
a necrotising myopathy with a macrophage predominant endomysial
and perimysial inﬁltrate and connective tissue fragmentation, MHC-I
expression and capillary and sarcolemmal deposition of MAC [121].
Fig. 5. Up-regulation of HMGCR antigen in regenerating muscle ﬁbres (arrows) in anti-HMGCR associated myopathy: A. anti-NCAM antibody; B. anti-HMGCR antibody; C. overlay image.
(Courtesy of Dr A. Mammen and the publisher [138]).
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tent the pathological phenotype is and if such cases represent a separate
entity or are merely part of a spectrum of disorders associated with
antisynthetase antibodies.Acknowledgements
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